secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2021-10-13T23:59:59+00:00
Accession:  0001193125-21-297915
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus BioSciences announces unexpected death of board member Alan C. Mendelson
--------------------------------------------------------------------------------

- Alan C. Mendelson passed away unexpectedly on October 8, 2021.
- He served as a director since January 2021 and as external legal counsel since Coherus' founding in 2010.
- Mendelson was a partner at Latham & Watkins and Cooley, and acted as general counsel at Amgen and Cadence.
- He served on boards of several public biotech companies including Aviron, CV Therapeutics, and QLT.
- CEO Denny Lanfear expressed condolences, noting Mendelson's profound impact on the company and industry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312521297915/0001193125-21-297915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312521297915/d237076d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-297915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer